论文部分内容阅读
目的 探讨传染性非典型肺炎临床治愈后胸部X线转归的相关因素。方法 选定年龄、性别、起病时体温、病变波及范围、开始使用激素治疗时间作为可能的相关因素 ,对 93例治愈出院的SARS患者 ,根据其出院时普通胸片检查结果做回顾性分析 ,对所得数据采用卡方检验进行统计学处理。结果 胸片表现未完全恢复正常者中男性 19例 (5 4 2 9% ) ,女性 16例 (4 5 71% ) ,P >0 0 1;年龄 4 5岁以上者 7例 (5 8 33% ) ,年龄 4 5岁以下者 2 8例 (34 5 7% ) ,P >0 0 1;起病表现为高热者 (体温≥39℃ ) 2 6例 (5 0 0 0 % ) ,起病表现为低热或中等程度发热者 9例 (2 1 95 % ) ,P <0 0 1;病变波及双侧肺野 ,或为单侧多发病灶者 2 2例 (5 2 38% ) ,单侧单发病灶者 13例 (2 5 4 9% ) ,P <0 0 1;开始使用激素治疗病程 5d之内者 2 2例 (38 6 0 % ) ,病程 5d以后开始使用激素治疗者 12例 (33 33% ) ,P >0 0 1。病程 7d之内开始使用激素治疗者 2 1例 (30 0 0 % ) ,病程 7d以后者 14例 (6 0 87% ) ,P <0 0 1。结论 肺部病变的最终转归主要与病情本身的严重程度有关 (在临床上表现为起病时高热 ,胸片提示病变波及双侧肺野 ) ,而与患者性别、年龄无明显相关性。过早使用激素治疗 (病程 5d之内 ) ,对肺部病变的最终转归
Objective To investigate the related factors of chest X-ray after the clinical cure of SARS. Methods A total of 93 patients with SARS who were discharged from hospital were retrospectively analyzed according to the results of their routine chest X-ray findings at the time of discharge. The age, sex, onset of fever and the extent of the disease were selected and the hormonal treatment time was started as a possible relevant factor. The data obtained using chi-square test for statistical analysis. Results 19 cases (5 429%) were males and 16 females (41 71%), P 0 01; 7 patients aged 45 years (5 8 33% ), 28 (34.57%) younger than 45 years of age, P> 0 01; 26 cases (600%) with onset of fever (≥39 ℃), onset 9 cases (2195%) with fever or moderate fever, P <0.01; pathological changes in both lung fields, or unilateral multiple lesions in 22 patients (52 38%), unilateral single Thirteen cases (25.49%) had lesions, P <0.01; 22 cases (38%) started hormone treatment within 5 days, and 12 cases %), P> 0 0 1. During the 7 days, 21 cases (30 0%) started hormone therapy and 14 cases (6 0 87%) after 7 days, P <0.01. Conclusions The final prognosis of pulmonary disease is mainly related to the severity of the disease itself (clinical manifestations are high fever on onset, chest X-ray suggests lesions affecting both lung fields), but not with patient’s gender and age. Premature use of hormone therapy (duration of 5d), the ultimate outcome of lung disease